| Title |
Safety and feasibility of electrical muscle stimulation in patients undergoing autologous and allogeneic stem cell transplantation or intensive chemotherapy
|
|---|---|
| Published in |
Supportive Care in Cancer, August 2018
|
| DOI | 10.1007/s00520-018-4390-z |
| Pubmed ID | |
| Authors |
M. Bewarder, A. Klostermann, M. Ahlgrimm, J. T. Bittenbring, M. Pfreundschuh, S. Wagenpfeil, D. Kaddu-Mulindwa |
| Abstract |
Intensive chemotherapy, with or without following autologous or allogeneic stem cell transplantation (HSCT), is often the only curative treatment option for patients with hematological malignancies and leave many survivors physically and psychologically impaired. Electrical muscle stimulation (EMS) is a proven tool to improve physical performance in seniors and patients with chronic diseases. We therefore investigated the safety and feasibility of EMS in 45 patients undergoing autologous HSCT (n = 13), allogeneic HSCT (n = 11) and intensive chemotherapy (n = 21). Furthermore, physical (assessed by 6-min walking distance (6MWD) and short physical performance battery (SPPB)) and psychological performance (assessed by multidimensional fatigue inventory (MFI) and the EORTC QOL-C30 questionnaire) were measured before chemotherapy (T1) and at discharge from hospital (T2). Four patients died due to septic shock, two withdrew consent before the start of EMS training and five stopped EMS training during the study because of chemotherapy-related complications, loss of motivation or loss of ability to use EMS autonomously. Thirty-four out of 45 (76%) patients used EMS throughout the study period and participated in physical and psychological tests at time points 1 and 2. EMS-related adverse events were hematoma (n = 1) and muscle pain (n = 2). No bleeding events > 1 according to the WHO bleeding scale occurred. Decline in 6MWD from T1 to T2 was 24 m. The SPPB score stayed the same with 11 points at T1 and T2. Most MFI subscales showed stable fatigue levels and quality of life (QoL) did not decrease significantly throughout therapy. EMS is feasible and safe in patients undergoing intensive chemotherapy. NCT03467087. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 79 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 11% |
| Researcher | 9 | 11% |
| Student > Ph. D. Student | 7 | 9% |
| Student > Bachelor | 6 | 8% |
| Other | 5 | 6% |
| Other | 9 | 11% |
| Unknown | 34 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Nursing and Health Professions | 13 | 16% |
| Medicine and Dentistry | 11 | 14% |
| Sports and Recreations | 7 | 9% |
| Engineering | 3 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 8 | 10% |
| Unknown | 35 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 April 2019.
All research outputs
#15,016,514
of 23,099,576 outputs
Outputs from Supportive Care in Cancer
#2,999
of 4,654 outputs
Outputs of similar age
#198,800
of 331,391 outputs
Outputs of similar age from Supportive Care in Cancer
#74
of 101 outputs
Altmetric has tracked 23,099,576 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,654 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,391 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.